10.6084/m9.figshare.11864811.v1 Motofumi Maruta Motofumi Maruta Takanori Miyoshi Takanori Miyoshi Naomi Matsuo Naomi Matsuo Takuya Yamashina Takuya Yamashina Kenji Irie Kenji Irie Minako Tsuruta Minako Tsuruta Hiroko Tsukada Hiroko Tsukada Moeko Tsuruyama Moeko Tsuruyama Masahisa Nagano Masahisa Nagano Yoichi Hiraki Yoichi Hiraki Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer Taylor & Francis Group 2020 5-fluorouracil advanced gastric cancer hemodialysis oxaliplatin pharmacokinetics platinum concentration 2020-02-18 09:58:50 Journal contribution https://tandf.figshare.com/articles/journal_contribution/Clinical_pharmacokinetics_of_oxaliplatin_in_a_hemodialysis_patient_with_advanced_gastric_cancer/11864811 <p>We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3 h prior to the start of a 4 h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for the second cycle. We performed an analysis of the PKs of L-OHP during these two cycles. Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively. A dose reduction of L-OHP by 30%−50% may be advisable for the initial administration, given the need for careful administration of chemotherapy in HD patients, with particular attention to the development of hematological toxicities and neuropathy.</p>